anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,150,293. Aspergillopeptidase. ASTRA A.B. 17 Aug., 1966 [27 Aug., 1965], No. 36836/66. Heading C3H. An aspergillopeptidase has the following properties: (a) it is proteolytically active against casein, hemoglobin and fibrin; (b) it has a proteolytic optimum for hemoglobin at pH 5À0-5À5; (c) it is able to reduce the adhesiveness and aggregation of blood platelets; (d) it is unable to hydrolyse N-a-tosyl-L-arginine ethyl ester or N-acetyl-L-tyrosine ethyl ester; (e) it has an ultra-violet absorption spectrum which is characteristic of proteins containing aromatic amino acids; (f) it has a molecular weight estimated by gel filtration to be lower than that of the aspergillopeptidase Protease 1 (which has a molecular weight of 20,000-30,000 determined by ultracentrifugation); (g) it is readily soluble in water, saline solution and conventional buffered solutions; (h) it is stable and retains its enzymatic activity at room temperature for more than a year in dry powdered form; (i) it is stable for more than two months in about neutral aqueous solution at 4‹ C., without substantial loss of its enzymatic activity; (j) it is stable in about neutral aqueous solution at 37‹ C., without substantial loss of its enzymatic activity, for more than 24 hours; (k) it is retarded during chromatography by a polymethacrylate or polyacrylate ion exchange resin equilibrated and eluted with 0À01 molar phosphate buffer at pH 7À5; (1) it is adsorbed by carboxymethyl cellulose at pH 5À5 and is eluted therefrom by ammonium acetate solution of a molarity of at least 0À005 and buffered at pH 7À5; (m) it is retarded during passage through a dextran-based cross-linked gel filtration material having a fractionation range for peptides and globular proteins of a molecular weight range of 1500 to 30,000 and having a fractionation range for dextrans of a molecular weight range of 500 to 10,000 so as to appear in the eluent with its maximum at about onethird of the difference in volume of eluent for glucose and for a dextran of molecular weight 500,000; (n) it passes without any significant adsorption through a column of a calcium phosphate or hydroxyl calcium phosphate which has been equilibrated and eluted with 0À001 molar phosphate buffer at pH 6.80. It may be prepared by cultivation of Aspergillus oryzae, treating the solution so obtained with an organic polymeric adsorbent containing carboxyl groups on a backbone of a polysaccharide, or on a polystyrene or polyacrylic ion-exchanger which preferentially adsorbs the aspergillopeptidase, and eluting with a buffer solution of pH 6 to 8. Other possible purification steps include gel electrophoresis, gel filtration, fractional precipitation, absorption chromatography, ion exchange chromatography, electrophoresis and dialysis; they may be preceded by treatment with tannin or lignin.
FIELD: microbiology. SUBSTANCE: invention relates to strains of microorganisms enterococci used in medicinal and food biotechnology. The strain Enterococcus faecium L-3 ND-79 VNIISCHM is designated for preparing curative-prophylactic agents and foodstuffs of curative- -prophylactic designation. The strain Enterococcus faecium L-3 shows resistance against broad spectrum of antibiotics, more expressed antagonism against pathogenic microorganisms, high viability and high level of production of vitamins of group "B" and folic acid. EFFECT: valuable properties of strain. 10 tbl, 8 ex
The invention discloses a method for synthesizing poly-substituted 2-aryl benzothiazoles by utilizing thiourea as a sulphur source. According to the method, thiourea reacts with benzyl chloride to generate an S-benzylisothiourea salt in situ. After that, through the aromatic nucleophilic substitution reaction of the obtained S-benzylisothiourea salt with 2-fluoronitrobenzene and then the one-step reduction (one-pot reaction) process, o-amino phenyl benzyl thioether as an intermediate product can be obtained. Finally, through the iron-catalyzed cross-dehydrogenative-coupling reaction of the o-amino phenyl benzyl thioether, a target product can be obtained. Compared with the traditional synthetic method, the method has the significant advantages of (1) short reaction step, wherein the target product can be synthesized through only three steps of simple reactions by utilizing simple chemical raw materials; (2) mild reaction condition, high atom economy, and relatively safe and cheap reaction reagents; (3) high reaction yield, good substrate tolerance and free of any dangerous or high-toxicity reagent. Therefore, the method might be applied to the large-scale production.
BACKGROUND: Lower urinary tract symptoms (LUTS) and mobility limitations are bidirectionally associated among older adults, but the role of skeletal muscle remains unknown. We evaluated cross-sectional associations of muscle health and physical performance with LUTS.
METHODS: We used data from 377 women and 264 men aged >70 years in the Study of Muscle, Mobility and Aging (SOMMA). LUTS and urinary bother were assessed using the LURN Symptom Index-10 (SI-10; higher = worse symptoms). Muscle mass and volume were assessed using D3-creatine dilution (D3Cr) and magnetic resonance imaging. Grip strength and peak leg power assessed upper/lower extremity physical performance. 400-m walk, Short Physical Performance Battery (SPPB), and Four Square Step Test (FSST) assessed global physical performance. Mobility Assessment Tool-short form (MAT-sf) assessed self-reported mobility. We calculated Spearman correlation coefficients adjusted for age, body mass index, multimorbidity, and polypharmacy, chi-square tests, and Fisher's Z-test to compare correlations.
RESULTS: Among women, LURN SI-10 total scores were inversely correlated with FSST (rs = 0.11, p = .045), grip strength (rs = -0.15, p = .006), and MAT-sf (rs = -0.18, p = .001), but not other muscle and physical performance measures in multivariable models. LURN SI-10 was not associated with any of these measures among men. Forty-four percent of women in the lowest tertile of 400-m walk speed versus 24% in the highest tertile reported they were at least "somewhat bothered" by urinary symptoms (p < .001), whereas differences among men were not significant.
CONCLUSIONS: Balance and grip strength were associated with LUTS severity in older women but not men. Associations with other muscle and physical performance measures varied by LUTS subtype but remained strongest among women.
Difficulties with walking in people with Parkinson's disease contribute to injurious falls and decreased quality of life. The Honda Walking Assist (HWA) robotic device is designed to assist individuals with gait impairments to take longer strides and walk faster. This study will investigate the impact of HWA usage on mobility in the home and community in individuals with PD. It will also examine feasibility and safety of HWA usage in the PD population. Specific Aim 1: Determine the short-term impact of mechanical gait assistance on efficiency and ease of walking in individuals with PD. With disease progression, individuals with PD develop gait impairments (e.g., slower gait velocity, shorter step lengths, increased step-to-step variability, and freezing of gait), that interfere with their abilities to perform daily living tasks and participate in work, home, and social activities and predispose them to falls. The investigators hypothesize that wearing the HWA device will improve gait efficiency, gait parameters, and perceived ease of walking in individuals with PD compared to unassisted walking over a one session period. Specific Aim 2: Determine the effect of long-term HWA device usage on the ease and ability to walk unassisted in the home and community in individuals with PD. Angular sensors embedded in the HWA monitor the cadence, angular velocity, and degree of hip extension and flexion of the device user. When the user initiates walking, the HWA automatically adjusts leg movements to reach target walk ratios (step length/cadence) by increasing the amount of hip flexion and/or extension using power supplied by the device. Thus, the HWA applies continuous, step-by-step cueing to individuals with PD to take bigger and more symmetrical steps, thereby producing a faster and more efficient walking pattern. By wearing the HWA device over an extended period of time, individuals with PD will repetitively practice walking with a more "normal" gait pattern, possibly driving neuroplastic changes that will translate to improve unassisted walking. The investigators hypothesize that an 8-week intervention of HWA device usage will improve gait efficiency, gait parameters, perceived ease of walking, self-confidence, and daily physical activity in the home and community in individuals with PD with and without the use of the device.
Eligible patients will undergo implant of the Soncloud-9 device within 1-5 weeks of completion of radiotherapy. About 1-3 weeks after surgery, patients will undergo sonication and intravenous administration of balstilimab, botensilimab and liposomal doxorubicin. Brain MRI will be done to quantify extent of blood brain barrier opening. The dose for balstilimab is 450 mg every 3 weeks. The dose for botensilimab is 1mg/kg every 6 weeks. The dose for liposomal doxorubicin is 30 mg every 3 weeks. Sonication and administration of study agents will continue every 3 weeks (21 days= 1 cycle) for a total of 9 cycles (approx. 6 months). Additional cycles may be considered if deemed beneficial and in the patient's best interest. Blood samples for circulating tumor DNA will also be collected before and after each sonication. The first 6 patients will comprise a safety run-in cohort with intensified safety monitoring through the end of the second cycle.
Participants (persons with dementia (PWD) and their family caregiver (CG)) and their primary care physicians in this group will receive an initial in-home needs assessment and then a written report indicating any unmet care needs identified and potential recommendations of care for meeting those needs. They will be able to pursue any interventions or treatments they or their treating physicians deem appropriate. They will also receive a standardized Aging and Caregiver Resource Guide developed in the previous MIND trial. The study team will perform another in-home needs assessment at 18 months and the written report along with recommendations for care will be provided to the family and the PWD's primary care physician.
FIELD: medicine, immunology. SUBSTANCE: invention reports about compositions and methods for enhancement of cytocide immune responses directed against preliminary taken cells type in mammals. Methods and compositions are based on the combination of immunoconjugate of type antibody-cytokine and angiogenesis inhibitor. In administration to mammal the immunoconjugate induces the response against preliminary taken cells type, for example, cancer cells that as result of synergetic effect with angiogenesis inhibitor exceeds the immune response induced by a single immunoconjugate. Methods and compositions are useful especially for eradication solid tumors or virus-infected mammalian cells. EFFECT: expanded assortment of immunomodulating agents. 27 cl, 5 dwg
These cases were identified from patient that lack of specific diseases; Non-use of antibiotics or immunosuppressive drugs. That the participants will be selected using convenience sampling method and randomly divided into three groups: combination of alcohol and povidone iodine 10%, Alcohol after and control groups. In the Intervention in one group the vascular access site disinfected with Alcohol(group1) and in group 2, Alcohol and povidone iodine 10% was used to separate were disinfected. Then the patient in a month of inflammation and infection of the vascular access will be monitor. Exclusion criteria: inflammation or fistula failure during the study for any reason other than infection. Sample size determination: Through the pilot study. Date: 02.10.2014 till 02.11.2014 Outcome: Washing with both solution affected on reduce the inflammation and infection of the patient.

the efficacy of Alcohol after Betadine and combination of alcohol and Betadine on inflammation and infection related to Vascular access hemodialysis patients.
Participants will be randomized to 1 of 2 different dose levels of maplirpacept (PF-07901801) which will be administered in combination with standard doses of tafasitamab and lenalidomide. Approximately 50 participants will be enrolled (25 per dose).
Stress urinary incontinence (SU) is a common problem among adult women . Pelvic floor muscle training (PFMT) is recommended as first line treatment but PFMT is not always efficient and some women cannot comply with the intensive PFMT needed to obtain effect because of weakened or damaged muscles caused by vaginal delivery and age related changes.

Hypothetically alternative methods could be used to enhance the effect of a strength-training program. A low intensity training program with a simultaneous partial occlusion of the blood supply for the training muscle, so called "Kaatsu" training has been found to increase muscle strength faster than ordinary strength training but with much less effort. It seems difficult to make occlusion of the pelvic floor muscles during PFMT but a study found that low intensity training of the quadriceps femoris with partial occlusion of the blood supply did not only increase muscle strength of the quadriceps femoris muscle but also of the biceps humeri muscle if that muscle was trained with low-load training and no occlusion in the same training session. The specific reason for this this "cross-transfer effect" could not be fully explained but it was believed to be caused by a systemic effect caused by growth hormones. The aim of this study is therefore to examine if Kaatsu training offered in relation to a low-load PFMT program can increase the effect of PFMT in women with SUI
Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill of d-cycloserine (DCS) one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
Group 3 will be recruited from the Endocrinology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) who currently do not have a diagnosis of neuropathy or a diabetic foot ulcer. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
BACKGROUND: There are few studies for detecting rhythm abnormalities among healthy children and adolescents. The aim of the study was to investigate the prevalence of abnormal electrocardiographic findings in the young Iranian population and its association with blood pressure and obesity.
METHODS: A total of 15084 children and adolescents were examined in a randomly selected population of Tehran city, Iran, between October 2017 and December 2018. Anthropometric values and blood pressure measurements were also assessed. A standard 12-lead electrocardiogram was recorded by a unique recorder, and those were examined by electrophysiologists.
RESULTS: All students mean age was 12.3 ± 3.1 years (6-18 years), and 52% were boys. A total of 2900 students (192.2/1000 persons; 95% confidence interval 186-198.6) had electrocardiographic abnormalities. The rate of electrocardiographic abnormalities was higher in boys than girls (p < 0.001). Electrocardiographic abnormalities were significantly higher in thin than obese students (p < 0.001), and there was a trend towards hypertensive individuals to have more electrocardiographic abnormalities compared to normotensive individuals (p = 0.063). Based on the multivariable analysis, individuals with electrocardiographic abnormalities were less likely to be girls (odds ratio 0.745, 95% confidence interval 0.682-0.814) and had a lower body mass index (odds ratio 0.961, 95% confidence interval 0.944-0.979).
CONCLUSIONS: In this large-scale study, there was a high prevalence of electrocardiographic abnormalities among young population. In addition, electrocardiographic findings were significantly influenced by increasing age, sex, obesity, and blood pressure levels. This community-based study revealed the implications of electrocardiographic screening to improve the care delivery by early detection.
The subjects in this group are set to play floorball three times pr. week for 39 weeks.
The mindfulness online resources consisted of 4 weekly modules. Mindfulness exercises, including body scan, mindful breathing, mindful eating, mindful walking, 3-min breathing space, and thought distancing exercise, are audio-recorded to facilitate participants to practice mindfulness. Readings and graphics are included to explain the concept of mindfulness and to share with participants the common difficulties that participants may come across during mindfulness practices.
Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
Apply a thin layer of DUOBRII Lotion once daily to cover only affected areas and rub in gently. If a bath or shower is taken prior to application, the skin should be dry before applying the lotion. 

The total dosage should not exceed approximately 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis [see Warnings and Precautions (5.2)]. Do not use with occlusive dressings unless directed by a physician. Discontinue treatment when control is achieved. Avoid application of DUOBRII Lotion on the face, groin, or in the axillae.

DUOBRII Lotion is not for oral, ophthalmic, or intravaginal use.
PURPOSE: An oil-in-water type cosmetic composition for UV protection is provided to easily adjust hardness and to improve applicability. CONSTITUTION: A cosmetic composition for UV protection contains silica, titanium dioxide, fatty acid, and fatty alcohol. The composition contains 0.01-5.0 wt% of the fatty acid and 0.01-8.0 wt% of the fatty alcohol. The fatty acid is selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, oleic acid, linoleic acid, arachidonic acid, and behenic acid. The fatty alcohol includes one or more among behehyl alcohol, cetearyl alcohol, cetyl alcohol, and stearyl alcohol. The cosmetic composition is prepared by emulsifying an oil ingredient containing the fatty acid and the fatty alcohol, and adding an oil ingredient containing hydrophilic silica and lipophilic titanium dioxide. [Reference numerals] (AA) Titanium dioxide, Silica(powder); (BB) Water phase; (CC) Oil; (DD) Fatty acid, Fatty alcohol
After appropriate screening and randomization, patients enrolled will receive TACE plus 2-cycle of Cadonilimab treatment before surgery. Four weeks later after surgery, Cadonilimab treatment will be followed up to 16 cycles.
The prevalence of overweight and obese people worldwide has dramatically increased in the last decades and is yet to peak. At the same time and partly due to obesity and associated assisted reproduction, twinning rates showed a clear rise in the last years. Adverse fetomaternal outcomes are known to occur in singleton and twin pregnancies in overweight and obese women. However, the impact of the obesity levels as defined by the World Health Organization on the outcomes of twin pregnancies has not been thoroughly studied. Therefore, the purpose of this study is to examine how maternal overweight, and the level of obesity affect fetomaternal outcomes in twin pregnancies, hypothesizing a higher likelihood for adverse outcomes with overweight and each obesity level. This is a retrospective cohort study with 2,349 twin pregnancies that delivered at the Buergerhospital Frankfurt, Germany between 2005 and 2020. The mothers were divided into exposure groups depending on their pre-gestational body mass index; these were normal weight (reference group), overweight and obesity levels I, II, and III. A multivariate logistic regression analysis was performed to assess the influence of overweight and obesity on gestational diabetes mellitus, preeclampsia, postpartum hemorrhage, intrauterine fetal death, and a five-minutes Apgar score below seven. The adjusted odds ratio for gestational diabetes compared to normal weight mothers were 1.47, 2.79, 4.05, and 6.40 for overweight and obesity levels I, II and III respectively (p = 0.015 for overweight and p < 0.001 for each obesity level). Maternal BMI had a significant association with the risk of preeclampsia (OR 1.04, p = 0.028). Overweight and obesity did not affect the odds of postpartum hemorrhage, fetal demise, or a low Apgar score. While maternal overweight and obesity did not influence the fetal outcomes in twin pregnancies, they significantly increased the risk of gestational diabetes and preeclampsia, and that risk is incremental with increasing level of obesity.
<P>PROBLEM TO BE SOLVED: To provide an optical driving method for a biofunctional molecule which causes a reversible structural change on the biofunctional molecule by using light, and to provide a micro-nanomachine.  <P>SOLUTION: The optical driving method for the biofunctional molecule is comprised of following two steps. In a first step, a cross-linking photochromic molecule represented by a formula (8) is connected to two thiol radicals in the biofunctional molecule to cross-link the thiol radicals, and the cross-linking photochromic molecule is transformed into a cis-type photochromic molecule by ultraviolet irradiation followed by shortening the distance of a cross-linking portion, to thereby obtain a first structure of the biofunctional molecule. In a second step, the cross-linking photochromic molecule is transformed into a trans-type photochromic molecule by visible light irradiation, and the distance of the cross-linking portion is extended, to thereby obtain a second structure of the biofunctional molecule. There is also provided the micro-nanomachine which is controlled by the optical driving method.  <P>COPYRIGHT: (C)2003,JPO